###### Strengths and limitations of this study

-   This updated meta-analysis included a larger number of studies involving more participants which adds precision to previous findings.

-   This study analysed both safety and efficacy, focusing on sexual functioning and quality of life measures because lower urinary tract symptoms treatment related adverse events have a hugely detrimental impact on ones' psychological well-being.

-   Quality assessment methods used did not highlight substantial differences between studies because blinding is not possible given the characteristics of the two interventions under investigation.

-   Due to the limited number of studies in this field, we were unable to conduct subgroup analysis around laser power (ie, 80W, 120W, 180W and so on) which is necessary to identify the most effective/efficient standard.

-   Surgical experience with laser technology, drop outs and withdrawals as well as other important factors were seldom reported in any detail which inhibits further analysis.

Introduction {#s1}
============

Lower urinary tract symptoms (LUTS) commonly occur in the ageing male population, affecting \>1 in 4 of those above 50 years of age. LUTS manifest through benign prostatic hyperplasia (BPH) and often have a hugely negative impact on quality of life (QoL).[@R1] Treatments for BPH range from medicinal interventions to surgery, where transurethral resection of the prostate (TURP) remains the surgical gold standard. Surgical therapy is recommended for patients whom have not benefitted from medical interventions such as, 5-alpha-reductase inhibitors and alpha-blockers.[@R1] TURP has been found to have a high success rate and low reintervention rate at long-term follow-up,[@R3] however; increasingly evidence indicates this invasive procedure is also associated with serious complications such as bleeding, urethral strictures, urinary incontinence and transurethral resection (TUR) syndrome.[@R4] Consequently, there is an urgent need to develop minimally invasive therapies which do not have such a negative impact on patients' lives.

Laser therapies offer a new direction in BPH therapies and photoselective vaporisation of the prostate (PVP) is increasingly being studied as a potential new first line treatment.[@R7] This technique is generally performed with a 532 nm green laser generated using potassium-titanyl-phosphate (KTP) or lithium triborate crystals.[@R12] Unlike other types of laser, the green laser is easily absorbed by soft tissue haemoglobin, while hardly at all by other fluid mediums, which leads to improved coagulation and lowers the risk of deeper tissue injuries during vaporisation.[@R13] Numerous studies provide supporting evidence of increased benefit, demonstrating that PVP has superior mid-term clinical efficacy compared with TURP across functional outcomes including International Prostate Symptom Score (IPSS), maximum flow rate (Qmax), postvoid residual volume (PVR), International Index of Erectile Function (IIEF) and QoL.[@R15]

In a previous meta-analysis published in 2013, Teng *et al* [@R17] found that PVP and TURP have similar treatment efficacies, although due to the minimally invasive nature, PVP offers several potential benefits. While this early research provided some optimism, studies have yet to compare sexual function outcomes or efficacy results at 24 months, and across all available randomised controlled trials (RCTs) and prospective studies. Consequently, we sought to conduct an updated systematic review and meta-analysis of high quality studies to support clinical decision-makers treating BPH.

Materials and methods {#s2}
=====================

Patient and public involvement {#s2-1}
------------------------------

Neither patients nor the public were involved in the design and planning of the study.

Literature search and article selection {#s2-2}
---------------------------------------

A comprehensive literature search was performed using biomedical databases including PubMed, EMBASE and the Cochrane Library up until October 2018. The following MeSH terms and free text words were used: benign prostatic hyperplasia, BPH, transurethral resection of the prostate, TURP, green-light laser, vaporization, photoselective vaporization of the prostate and PVP. These terms were used singly and in combination (for further details please see [online supplement file 1](#SP1){ref-type="supplementary-material"}). Additionally, manual searches were commenced for references and citations included within pertinent reviews. Language was restricted to English and the search and selection strategy was designed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement.[@R18] Randomised controlled trials and prospective studies meeting the following criteria were included: (1) studies comparing the safety and efficacy of PVP versus TURP for surgical treatment of LUTS secondary to manifesting BPH, (2) endpoints such as treatment-related adverse events and functional outcomes such as IPSS, Qmax, PVR, QoL and IIEF when available, and (3) providing the full text of the study could be accessed.
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Literature searching, selection and data extraction was undertaken independently by two reviewers (SL and PP) which was then cross-checked. Any discrepancies were resolved through discussion. A flowchart representing the search and selection process is presented in [figure 1](#F1){ref-type="fig"}.

![Preferred Reporting Items for Systematic Reviews and Meta-Analyses flowchart.](bmjopen-2018-028855f01){#F1}

Assessment of study quality {#s2-3}
---------------------------

Study quality was assessed in accordance with criteria recommended by the Oxford Centre for Evidence Based Medicine.[@R19] Methodological reporting quality of RCTs was assessed using Jadad[@R20] and the Newcastle--Ottawa scale[@R21] was used to evaluate the quality of the prospective cohort studies included.

Data extraction and statistical analysis {#s2-4}
----------------------------------------

Preoperative parameters were extracted together with intraoperative data including operation times, changes in haemoglobin and transfusion rates. Postoperative data including length of hospitalisation, duration of catheterisation and treatment-related complications were also analysed. Functional results including IPSS, Qmax, PVR, QoL and IIEF were assessed at 3, 6, 12, 24, 36 and 60 months after surgery.

Mean difference (MD) was used to assess continuous parameters. Authors were contacted when data were expressed as medians with corresponding range values. Otherwise, the statistical formula elaborated by Hozo *et al* [@R22] was implemented to back-calculate means and SD in accordance with the recommended methods described in the Cochrane Handbook for Systematic Reviews.[@R23]

Results were expressed as risk ratios (RR) with corresponding 95% CI for dichotomous variables. I^2^ was utilised to assess heterogeneity across studies. An I^2^\<50% is generally considered an acceptable level of heterogeneity therefore a fixed effect model was applied. In instances where the I^2^\>50% a random-effects model was applied as is the standard procedure for higher levels of heterogeneity. Pooled effects were synthesised using Z test and a p value \<0.05 was set at the threshold for statistical significance.

Sensitivity analysis {#s2-5}
--------------------

Sensitivity analysis was conducted to assess the reliability of the findings of this study. As such, Qmax at 24 months, PVR at 3 months, operation times and period of hospitalisation were further analysed by removing non-RCTs. All data analyses were conducted with Review Manager V.5.3 software.

Results {#s3}
=======

The predetermined search and selection criteria yielded 22 publications,[@R2] reporting 19 separate clinical studies. Three studies (ie, Bachman *et al*,[@R10] Thomas *et al* [@R30]) refer to an identical study, and two studies[@R24] [@R31] were from the same trials over different periods of time. In total, there were 2665 patients involved, 1455 of whom had been treated with PVP and 1210 with TURP. Patient characteristics and study characteristics are summarised in [table 1](#T1){ref-type="table"}. Overall, RCTs included in this meta-analysis can be considered of reasonably high quality with eight studies achieving a score of 3, while seven slightly lower quality achieved Jadad scores of 2. All prospective studies included can be considered high quality having been awarded nine using the Newcastle-Ottowa Scale.

###### 

Baseline characteristics of comparative studies

  Authors and year                         Design   Group   Laser power (W)   No of patients          Age (years)                 Prostate size (mL)          IPSS                  Qmax (mL/s)               PVR (mL)                  QoL                   IIEF                  Follow-up (months)   LE   Study quality
  ---------------------------------------- -------- ------- ----------------- ----------------------- --------------------------- --------------------------- --------------------- ------------------------- ------------------------- --------------------- --------------------- -------------------- ---- ---------------
  Kumar *et al,* 2013[@R24]                RCT      PVP     120               58                      64.58±6.64                  52.79±16.13                 20.05±2.75            6.68±2.00                 143.35±52.67              3.60±1.01             16.65±2.80            12                   2a   3\*
                                                    TURP                      60                      63.68±6.57                  52.20±15.93                 20.71±2.68            7.00±1.97                 139.25±54.28              3.73±0.97             16.95±2.86                                       
  Lukacs *et al* 2012[@R2]                 RCT      PVP     120               68                      66.9±7.8                    50.54±16.53                 22 (17--26)**^%^**    7.79±2.75                 89.5 (30, 158)**^%^**     70 (68, 80)**^%^**                          12                   2a   3\*
                                                    TURP                      68                      67.6±7.6                    50.11±14.73                 20 (15--23)**^%^**    7.76±2.64                 75 (28,126)**^%^**        75 (65, 85)**^%^**                                                     
  Pereira-Correia *et al* 2012**[@R25]**   RCT      PVP     120               10                      66.4 (52, 76)**^\$^**       43.4 (30, 58)**^\$^**       22 (9, 33)**^\$^**    10 (3, 18)**^\$^**        150 (25, 250)**^\$^**                           23 (22, 24)**^\$^**   24                   2a   2\*
                                           TURP             10                63.5 (56, 78)**^\$^**   47 (30, 60)**^\$^**         25 (15, 31)**^\$^**         6.4 (4,11)**^\$^**    177 (50, 300)**^\$^**                               23 (22, 25)**^\$^**                                                   
  Capitan *et al* 2011[@R7]                RCT      PVP     120               50                      69.8±8.44                   51.29±14.72                 23.74±5.24            8.03±3.14                                           4.52±0.27                                   12                   2a   3\*
                                                    TURP                      50                      67.7±6.7                    53.10±13.75                 23.52±4.38            3.88±2.71                                           4.14±1.06                                                              
  Al-Ansari *et al* 2010[@R26]             RCT      PVP     120               60                      66.3±9.4                     61.8±22                    27.2±2.3              6.9±2.2                   53.2±25                                                               36                   2a   3\*
                                                    TURP                      60                      67.1±8                       60.3±20                    27.9±2.7              6.4±2                     57±21                                                                                            
  Xue *et al* 2013[@R27]                   RCT      PVP     120               100                     72.1±11.3                   65.8±23.6                   23.0±5.1               8.0±3.6                  148.3±101.6               4.2±0.9                                     36                   2a   2\*
                                                    TURP                      100                     71.0±10.8                   67.3±24.7                   23.2±5.0               8.2±3.8                  151.1±105.2               4.3±0.8                                                                
  Horasanli *et al* 2008[@R38]             RCT      PVP     80                39                      69.2±7.1                    86.1±8.8                    18.9±5.1              8.6±5.2                   183±50.1                                        19.9±5.1              6                    2a   2\*
                                                    TURP                      37                      68.3±6.7                    88±9.2                      20.2±6.8              9.2±5.6                   176.9±45.3                                      20.1±5.5                                         
  Mohanty *et al* 2012[@R28]               RCT      PVP     80                60                      66.68±8.62                  44.77±14.09                 19.98±3.27            7.41±2.07                 145.8±70.33               3.97±0.82             17.98±3.55            12                   2a   3\*
                                                    TURP                      57                      65.74±9.09                  49.02±15.93                 20.88±3.87            6.75±1.63                 143.23±65.96              3.91±0.78             17.40±4.76                                       
  Bouchier-Hayes *et al* 2009**[@R11]**    RCT      PVP     80                60                      \>50                                                    25.28±5.93            8.81±2.55                 129.2±155.7 111.3±113.7   4.74±1.23                                   12                   2a   3\*
                                                    TURP                      59                                                                              25.41±5.72            8.86±2.99                                           5.08±0.94                                                              
  Bachmann *et al* 2014**[@R10]**          RCT      PVP     180               136                     65.9±6.8                    48.6±19.2                   21.2±5.9              9.5±3.0                   110.1±88.5                4.6±1.1               13.2±7.6              6                    2a   3\*
                                           TURP             133               65.4±6.6                46.2±19.1                   21.7±6.4                    9.9±3.5               109.8±103.9               4.5±1.4                   13.7±7.5                                                              
  Bachmann *et al* 2015**[@R29]**          RCT      PVP     180               136                     65.9±6.8                    48.6±19.2                   21.2±5.9              9.5±3.0                   110.1±88.5                4.6±1.1               13.2±7.6              12                   2a   2\*
                                           TURP             133               65.4±6.6                46.2±19.1                   21.7±6.4                    9.9±3.5               109.8±103.9               4.5±1.4                   13.7±7.5                                                              
  Thomas *et al* 2016[@R30]                RCT      PVP     180               136                     65.9±6.8                    48.6±19.2                   21.2±5.9              9.5±3.0                   110.1±88.5                4.6±1.1               13.2±7.6              24                   2a   3\*
                                                    TURP                      133                     65.4±6.6                    46.2±19.1                   21.7±6.4              9.9±3.5                   109.8±103.9               4.5±1.4               13.7±7.5                                         
  Telli *et al* 2015[@R32]                 RCT      PVP     120               39                      67 (51, 87)**^\$^**         60 (41, 75)**^\$^**         20 (12, 30)**^\$^**   10.6 (5, 17)**^\$^**      60 (20, 220)**^\$^**                                                  24                   2a   2\*
                                                    TURP                      62                      69 (56, 87)**^\$^**         55 (40, 72)**^\$^**         19 (10, 31)**^\$^**   12.5 (3, 21)**^\$^**      65 (10, 220)**^\$^**                                                                             
  Kumar *et al* 2016**[@R31]**             RCT      PVP     120               58                      64.58±6.64                  52.79±16.13                 20.05±2.75            6.68±2.00                 143.35±52.67              3.60±1.01             16.65±2.80            36                   2a   2\*
                                                    TURP                      60                      63.68±6.57                  52.20±15.93                 20.71±2.68            7.00±1.97                 139.25±54.28              3.73±0.97             16.95±2.86                                       
  Mordasini *et al* 2018[@R39]             RCT      PVP     80                112                     68.4±8.7                    36.1±11.5                   20.3±7.0              8.9±4.1                   91.1±88.3                 4.2±1.1                                     60                   2a   2\*
                                                    TURP                      126                     67.6±8.4                    37.9±14.3                   20.4±7.5              8.5±4.6                   114.5±136.4               4.3±14                                                                 
  Chen *et al* 2011                        PCS      PVP     160               57                      69.5±7.4                    60.2±27.8                   19.7±6.0              6.9±4.0                   93.7±79.7                                                             6                    2b   9†
                                                    TURP                      51                      67.1±6.9                    58.3±26.2                   21.8±7.3              6.8±2.3                   102.2±70.1                                                                                       
  Bachmann *et al* 2005[@R37]              PCS      PVP                       37                      71.0±9.3                    65.1±36.9                   18.1±5.9              6.9±2.2                   146.1±106.9 120.7±49.0    3.3±1.7                                     6                    2b   9†
                                                    TURP                      64                      68.7±7.9                    48.9±21.2                   17.3±6.3              6.9±2.2                                             3.4±1.6                                                                
  Ruszat *et al* 2008[@R8]                 PCS      PVP     80                113                     62.3±5.0                    56.3±27.4                   20±6.4                8.5±4.1                   203±226                                                               24                   2b   9†
                                                    TURP                      75                      61.7±5.5                    45.3±21.0                   19±6.9                9.8±5.0                   104±108                                                                                          
                                                    PVP                       91                      75.0±2.8                    64.8±26.8                   18.6±5.8              7.3±2.7                   215±247                                                                                          
                                                    TURP                      40                      74.0±2.6                    54.2±21.2                   16.0±7.1              9.2±5.4                   124±141                                                                                          
                                                    PVP                       65                      84.3±3.1                    69.3±32.7                   14.1±7.4              7.1±4.2                   200±219                                                                                          
                                                    TURP                      12                      82.4±2.8                    44.9±22.1                   15.5±6.7              7.6±3.9                   231±350                                                                                          
  Tasci *et al* 2008[@R33]                 PCS      PVP                       40                      71.8±5.9                    108.4±15.8                  22.3±5.6              6.2±2.2                   116.5±60.5                3.6±0.7                                     24                   2b   9†
                                                    TURP                      41                      70.1±5.4                    104.2±12.5                  22.6±3.9              6.5±1.8                   110.7±59.8                3.5±0.6                                                                
  Tugcu *et al* 2008[@R33]                 PCS      PVP                       112                     67.5±7.4                    49.1±11.9                   17.9±4.9              6.9±1.9                   107.9±63.0 100.3±57.1     3.4±0.6                                     24                   2b   9†
                                                    TURP                      98                      66.3±7.9                    47.7±8.4                    17.7±3.5              7.2±1.7                                             3.4±0.5                                                                
  Nomura *et al* 2009[@R35]                PCS      PVP     80                78                      72.0 (67.0, 78.0)**^\$^**   50.5 (38.6, 70.3)**^\$^**   23 (17, 27)**^\$^**   6.8 (5.2, 9.5)**^\$^**    69 (31, 139)**^\$^**      5 (5, 6)**^\$^**                            12                   2b   9†
                                                    TURP                      51                      70.5 (66.5, 76.0)**^\$^**   42.8 (34.6, 54.0)**^\$^**   22 (16, 27)**^\$^**   7.3 (5.3, 10.2)**^\$^**   60 (31, 140)**^\$^**      5 (4, 5)**^\$^**                                                       
  Guo *et al* 2015[@R36]                   PCS      PVP     80                257                     69.7±8.9 66.4±8.4           52.3±19.3 44.2±19.1         19.4±6.3 18.4±6.3     8.3±6.0                   119.5±83.8 95.6±98.4      3.7±1.7 3.7±1.3                             60                   2b   9†
                                                    TURP                      104                                                                                                   10.0±5.2                                                                                                                   

Continuous variables were expressed as (mean±SD), mean (range)^\$^ or median (IQR)^%^.

Bachmann *et al,* 2014[@R10] Bachmann *et al,* 2015 and[@R30] Thomas *et al,* 2016 are from the same trials in different period.[@R24] Kumar *et al,* 2013 and Kumar *et al,* 2016 are from the same trials in different period.

\*Using Jadad scale (score from 0 to 5).

†Using Newcastle-Ottawa Scale (score from 0 to 9).

IIEF, international index of erectile function; IPSS, International Prostate Symptom Score;LE, level of evidence; PCS, prospective cohort study; PVP, photoselective vaporisation of the prostate; PVR, postvoid residual volume; Qmax, maximum flow rate; QoL, quality of life;RCT, randomised controlled trial; TURP, transurethral resection of the prostate.

Meta-analysis of functional outcomes {#s3-1}
------------------------------------

Baseline data including IPSS, Qmax, PVR, QoL and IIEF for all participants in both the PVP and TURP groups were similar ([table 2](#T2){ref-type="table"}).

###### 

Meta-analytical outputs summarising baseline parameters of PVP compared with TURP

  Parameter   No of studies   Sample size   Heterogeneity (Total)   Mean difference (95% CI)   Test for overall effect                                                   
  ----------- --------------- ------------- ----------------------- -------------------------- ------------------------- ---- -------- ------------------------ -------- --------
  IPSS                                                                                                                                                                   
   Baseline   14              1179          989                     11.32                      13                        0    0.58     −0.29 (--0.68 to 0.10)   Z=1.47   P=0.14
  Qmax                                                                                                                                                                   
   Baseline   14              1179          989                     70.23                      13                        81   \<0.01   0.05 (--0.51 to 0.61)    Z=0.17   P=0.87
  PVR                                                                                                                                                                    
   Baseline   12              1016          864                     9.24                       11                        0    0.6      2.19 (--3.22 to 7.6)     Z=0.79   P=0.43
  QoL                                                                                                                                                                    
   Baseline   10              910           766                     11.15                      9                         19   0.27     0.01 (--0.07 to 0.10)    Z=0.33   P=0.74
  IIEF                                                                                                                                                                   
   Baseline   5               351           297                     1.58                       4                         0    0.81     −0.13 (--0.86 to 0.60)   Z=0.34   P=0.73

IIEF, International Index of Erectile Function; IPSS, International Prostate Symptom Score; PVP, photoselective vaporisation of the prostate; PVR, postvoid residual volume; Qmax, maximum flow rate; QoL, quality of life; RR, risk ratio; TURP, transurethral resection of the prostate.

IPSS at 3-month, 6-month, 12-month and 24-month follow-up {#s3-2}
---------------------------------------------------------

Pooled analysis suggests there is no significant difference in IPSS at the 3-month, 6-month or 24-month follow-up points. At 3 months the MD=0.01 (p=0.85) please see [figure 2 a1](#F2){ref-type="fig"}. At 6 months the MD=0.30 (p=0.15), see [figure 2 a2](#F2){ref-type="fig"}. At the 12-month follow-up stage, there was a statistically significant difference with a MD=−0.10 (p\<0.01), see [figure 2 a3](#F2){ref-type="fig"}, however; at 24 months, there was no significant difference (MD=0.02, p=0.92), see [figure 2 a4](#F2){ref-type="fig"}.

![Forest plot of IPSS at 3 months (a1), 6 months (a2), 12 months (a3) and 24 months (a4); forest plot of Qmax at 3 months (b1), 6 months (b2), 12 months (b3) and 24 months (b4); forest plot of Pvr at 3 months (c1), 6 months (c2), 12 months (c3) and 24 months (c4); forest plot of QoL at 3 months (d1), 6 months (d2), 12 months (d3) and 24 months (d4); forest plot of IIEF at 3 months (e1), 6 months (e2), 12 months (e3) and 24 months (e4). IIEF, International Index of Erectile Function; IPSS, International Prostate Symptom Score; PVR, postvoid residual volume; Qmax, maximum flow rate; QoL, quality of life](bmjopen-2018-028855f02){#F2}

Qmax at 3-month, 6-month, 12-month and 24-month follow-up {#s3-3}
---------------------------------------------------------

Pooled analysis suggests there is no significant difference between PVP and TURP regarding Qmax at the 3-month follow-up stage with an MD=−0.07 (p=0.91), see [figure 2 b1](#F2){ref-type="fig"}. At the 6-month follow-up the MD=−0.17 (p=0.67), see [figure 2 b2](#F2){ref-type="fig"}. At 12 months, Qmax measures were slightly higher in the PVP group (MD=0.62), which may be considered a statistically significant difference (p=0.03), although only *borderline* when considering confidence intervals (95% CI 0.06 to 1.19), see [figure 2 b3](#F2){ref-type="fig"} for details. At 24 months, the MD=0.74 although was again non significant (p=0.34), see [figure 2 b4](#F2){ref-type="fig"} for details. However, an extreme level of heterogeneity were observed (I*^2^*=91%) hence sensitivity analysis was conducted at the 24-month follow-up point which yielded an MD=0.26, although this was not a significant finding (p=0.72), see [figure 3a](#F3){ref-type="fig"}.

![Sensitivity analysis of the Qmax at 24-month follow-up (A); PVR at 3-month follow-up (B); operation times (C); and period of hospitalisation (D). PVR, postvoid residual volume; Qmax, maximum flow rate.](bmjopen-2018-028855f03){#F3}

PVR at 3-month, 6-month, 12-month and 24-month follow-up {#s3-4}
--------------------------------------------------------

PVR between the two groups, yielded no significant difference at 3 months (MD=6.65, p=0.16), see [figure 2 c1](#F2){ref-type="fig"}, at 6 months (MD=2.07, p=0.35), see [figure 2 c2](#F2){ref-type="fig"}, at 12 months (MD=0.85, p=0.11), see [figure 2 c3](#F2){ref-type="fig"}, or at the 24-month follow-up point (MD=1.58, p=0.23), see [figure 2 c4](#F2){ref-type="fig"}. Again, a high level of heterogeneity (I*^2^*=93%) was observed and so sensitivity analysis was conducted at the 3-month follow-up juncture. This did not highlight a significant difference between groups (p=0.38), see [figure 3b](#F3){ref-type="fig"} for details.

QoL at 3-month, 6-month, 12-month and 24-month follow-up {#s3-5}
--------------------------------------------------------

There was no clinically relevant difference in QoL across the time points analysed. At the 3-month point, there was an MD=0.02, (p=0.59) see [figure 2 d1](#F2){ref-type="fig"}. However; there was one statistically significant difference at 6 months (MD=−0.08), although this is not clinically relevant and can only be considered of borderline significance (95% CI --0.13 to --0.02), despite the low p value (p=0.007), see [figure 2 d2](#F2){ref-type="fig"}. At 12 months (MD=0.01, p=0.75), see [figure 2 d3](#F2){ref-type="fig"} and at 24 months (MD=−0.07, p=0.10), see [figure 2 d4](#F2){ref-type="fig"}, there was no significant difference.

IIEF at 6-month, 12-month and 24-month follow-up {#s3-6}
------------------------------------------------

An analysis of sexual functioning was performed using IIEF. There was no significant difference between the two groups in terms of the IIEF at the 3-month point (MD=−0.06, p=0.76) see [figure 2 e1](#F2){ref-type="fig"}, at the 6-month (MD=−0.07, p=0.78) see [figure 2 e2](#F2){ref-type="fig"} or at the 12-month point (MD=−0.06, p=0.82) see [figure 2 e3](#F2){ref-type="fig"}. Pooled analysis does highlight a lower IIEF at the 24-month follow-up in the PVP group compared with the TURP group with a MD=−0.68, which is statistically significant but again must be interpreted with caution because to the upper CI is so close to zero (95% CI −1.20 to −0.15, p=0.01), see [figure 2 e4](#F2){ref-type="fig"}.

Meta-analysis of perioperative parameters {#s4}
=========================================

Operation time {#s4-1}
--------------

Fourteen studies comparing PVP against TURP reported operation times. Overall, TURP takes less time than PVP with a MD=15.24 min, and this was a significant finding (p\<0.01) see [table 3](#T3){ref-type="table"}. However, there was extreme heterogeneity across this sample (I*^2^*=94%). As such, sensitivity analysis was conducted by removing low-quality trials ([figure 3c](#F3){ref-type="fig"}) which lowered the level of heterogeneity (I*^2^*=17%) and lowered the MD to 10.60 min (95% CI 8.39 to 12.81, p\<0.01), see [table 3](#T3){ref-type="table"}.

###### 

Meta-analytical outputs for the safety of PVP compared with TURP

  Outcomes                   No of studies   Sample size   Heterogeneity (total)   MD or RR (95% CI)   Test for overall effect                                                         
  -------------------------- --------------- ------------- ----------------------- ------------------- ------------------------- ------ ---------- -------------------------- -------- ----------
  Operation time             14              979           870                     216.27              13                        94     \<0.01     15.24 (8.91 to 21.54)      4.72     \<0.01
                             6\*             429\*         428\*                   6.01\*              5\*                       17\*   0.31\*     10.60 (8.39 to 12.81)\*    9.40\*   \<0.01\*
  Hospitalisation time       11              819           723                     600.62              10                        98     \<0.01     −1.98 (−2.56 to −1.39)     6.59     \<0.01
                             3\*             240\*         229\*                   6.29\*              2\*                       68\*   \<0.01\*   −1.83 (−2.25 to −1.40)\*   8.42\*   \<0.01\*
  Catheterisation time       14              861           794                     964.75              13                        99     \<0.01     −1.25 (−1.58 to −0.92)     7.48     \<0.01
  Blood loss                 6               389           335                     46.05               5                         89     \<0.01     −1.33 (−2.05 to −0.61)     3.62     \<0.01
  Transfusion                14              1110          946                     10.87               13                        0      0.62       0.14 (0.08 to 0.26)        6.10     \<0.01
  TUR syndrome               7               590           435                     0.73                6                         0      0.99       0.19 (0.06 to 0.61)        2.82     \<0.01
  Capsular perforation       7               641           451                     1.84                6                         0      0.93       0.09 (0.03 to 0.26)        4.51     \<0.01
  Clot retention             8               699           504                     1.72                7                         0      0.97       0.14 (0.07 to 0.29)        5.32     \<0.01
  Urinary tract infection    13              1049          860                     8.79                12                        0      0.72       1.15 (0.85 to 1.55)        0.89     0.38
  Acute urinary retention    10              694           653                     5.55                9                         0      0.78       1.19 (0.80 to 1.75)        0.86     0.39
  Urinary incontinence       4               296           263                     4.28                3                         30     0.23       1.45 (0.74 to 2.86)        1.08     0.28
  Bladder neck contracture   8               523           520                     4.32                7                         0      0.74       1.05 (0.57 to 1.94)        0.16     0.87
  Urethral stricture         15              1172          980                     9.37                14                        0      0.81       0.81 (0.57 to 1.16)        1.14     0.25
  Retrograde ejaculation     4               320           314                     15.06               3                         80     \<0.01     0.72 (0.49 to 1.07)        1.62     0.11
  Dysuria                    12              1079          854                     24.80               11                        58     0.01       1.76 (1.17 to 2.65)        2.71     \<0.01
  Reintervention             12              980           809                     14.58               11                        25     0.20       1.81 (1.28 to 2.56)        3.35     \<0.01

\*Using sensitivity analysis.

MD, mean difference; PVP, photoselective vaporisation of the prostate; RR, risk ratio; TR, syndrome=transurethral resection syndrome; TURP, transurethral resection of the prostate.

Operative blood loss {#s4-2}
--------------------

Six studies involving 724 participants (PVP n=389, TURP n=335) provided blood loss estimates during operations. The pooled statistic suggested that the drop in haemoglobin levels in the PVP group was significantly lower than in the TURP group with a MD of --1.33 g/dL (p\<0.01), see [table 3](#T3){ref-type="table"} for details.

Periods of hospitalisation {#s4-3}
--------------------------

Eleven studies involving 1542 participants met our inclusion criteria for the analysis of periods of hospitalisation. Pooled statistics highlighted a significant reduction in hospitalisation times with a MD=−1.98 days (p\<0.01) for PVP compared with TURP. However, again the level of heterogeneity across this sample was extreme (I*^2^*=98%) therefore sensitivity analysis ([figure 3d](#F3){ref-type="fig"}) was again performed although this had a negligible impact on the results (MD=−1.83 days, 95% CI −2.25 to −1.40, p\<0.01). See [table 3](#T3){ref-type="table"} for further details.

Catheterisation time {#s4-4}
--------------------

Fourteen available studies including 1655 participants (861 in the PVP group and 794 in the TURP group) were involved in this meta-analysis. Pooled data revealed that the PVP group had a significantly shorter catheterisation time with an MD=−1.25 days, (p\<0.01) see [table 3](#T3){ref-type="table"}.

Meta-analysis of complications {#s5}
==============================

Perioperative complications {#s5-1}
---------------------------

The overall effect of perioperative complications including bleeding-related transfusion, TUR syndrome, capsular perforation, clot retention, urinary tract infection and acute urinary retention are summarised in [table 3](#T3){ref-type="table"}. According to this meta-analysis, PVP was found to have significantly lower incidence of transfusion with an RR=0.14 (p\<0.01), and clot retention (RR=0.14, p\<0.01). There was also a substantial and significant difference in the occurrence of TUR syndrome (RR=0.19, p\<0.01) and capsular perforations (RR=0.09, p\<0.01). Furthermore, PVP appears to have a higher risk of mild to moderate dysuria (RR=1.76, 95% CI 1.17 to 2.65, p\<0.01), although there was no substantial or significant difference regarding urinary tract infection (RR=1.15, 95% CI 0.85 to 1.55, p=0.38) or acute urinary retention rate (RR=1.19, 95% CI 0.80 to 1.75, p=0.39).

Long-term complications {#s5-2}
-----------------------

Analysis of long-term complications such as bladder neck contracture, retrograde ejaculation and urethral stricture, suggests there is no significant difference between PVP and TURP. Bladder neck contracture (RR=1.05, p=0.87), retrograde ejaculation (RR=0.72, p=0.11) and urethral stricture (RR=0.81, p=0.25), see [table 3](#T3){ref-type="table"} for further details. However, PVP was found to have a significantly higher risk of re-intervention (RR=1.81, p\<0.01) see [table 3](#T3){ref-type="table"} for details.

Discussion {#s6}
==========

Over the last two decades, TURP has remained the gold standard surgical intervention for symptomatic BPH despite having high rates of treatment-related morbidities and complications which have a hugely negative impact on \~20% of those receiving this intervention.[@R3] Urologists continue to search for safer techniques without diminishing clinical efficacy compared with TURP.

Endoscopic technologies are being developed, and PVP emerged as a promising intervention which attracted our attention because this is a minimally invasive surgical procedure. The first generation PVP laser system utilised high-powered KTP lasers (60W) at 532 nm and was initially introduced in 1998.[@R40] More advanced generations including the KTP laser (80W), the Green-light high-performance system laser (120W), the Green-light lithium triboride laser (160W) and the Green-light X-ray photoelectron spectroscopy (XPS) laser (180W) systems were then sequentially introduced up until 2018, raising hopes of treating symptomatic BPH, effectively and safely.

Previous research comparing PVP and TURP has demonstrated that there is no significant difference in medium-term efficacy or safety when treating BPH, however; the long-term efficacy between these two techniques remains controversial. In this updated systematic review and meta-analysis, we reviewed all available RCTs and prospective studies (n=22) up until October 2018 which involved a total of 2665 participants. Pooled analyses and sensitivity analysis suggests both PVP and TURP have similar long-term function outcomes, which were analysed using both subjective (IPSS, QoL) and objective (Qmax, PVR) measures. IPSS at 12-month follow-up, Qmax at 6 months and QoL at 12 months highlighted a statistically significant difference, although the differences were only small.

This study adds to the current evidence base in terms of understanding sexual functioning post-intervention. Previous clinical studies have evaluated retrograde ejaculation rates, although conclusions could not be provided with any authority because findings were generally inconsistent and gathered over relatively short periods of time.[@R7] The longest running RCT which compared PVP with TURP had a 60-month follow-up, and suggested there is similar improvement in IPSS, Qmax, PVR, QoL and IIEF.[@R36]

Previously conducted meta-analyses have not had the opportunity to evaluate IIEF due to the relatively small number of studies collecting and reporting this particular outcome. Fortunately, IIEF is increasingly being used to analyse sexual functioning which enabled us to design and perform this meta-analysis given the increased availability of evidence in this area. Pooled analysis, however, suggests there is no significant difference in the retrograde ejaculation rate nor is there a significant difference in IIEF outcomes between PVP and TURP.

This meta-analysis did highlight substantial differences in perioperative factors analysed across this sample of studies. Pooled analyses and sensitivity analyses show that operation times are significantly longer for PVP, whereas the duration of hospitalisation and catheterisation are significantly shorter. Prolonged operative duration involved in PVP interventions appears to be associated with laser power and individual surgeon's experience and related skills. Laser power is determined for each individual device, and evidence from previous studies suggest that overall operation times are prolonged by \~23 min for PVP with an 80W laser, \~9 min with 120W and 7 min with 120W and 160W lasers. Furthermore, literature shows a surgeon's overall technical skills and confidence place him/her at a point on a learning curve for new technologies which is likely to be an important factor in the length of operations.

Safety is another key issue because the most serious TURP complications, such as bleeding and TUR syndrome are known to correlate with prostate size and longer operative times.[@R6] This analysis highlighted additional benefits, in that the incidence of perioperative complications including bleeding, blood transfusion, clot retention, capsule perforation and TUR syndrome are significantly lower for those receiving the PVP intervention. Although this can be explained by the characteristics of the green light laser, where the 532 nm wavelength is easily absorbed by haemoglobin in prostatic tissues but not by water.[@R13] Likewise in vaporisation, high-power laser energy is instantly absorbed by the blood, ensuring quicker vaporisation into the tissue which creates a prostate cavity with minimal blood loss.[@R42]

Other bleeding-related complications occur less frequently for those receiving PVP. However, another possible explanation could be that KTP laser energy penetrates only 1--2 mm of tissue. Therefore, high-power laser energy might be concentrated into the surface coat of prostatic tissue, which then ensures rapid vaporisation, leaving a 0.2 cm rim of residual coagulated tissue.[@R13] It may also be the case that the fluid medium used for PVP procedures is saline solution rather than glycine, therefore TUR syndrome does not occur in PVP. However, further research is necessary to understand this treatment-related complication.

Additional postoperative complications such as acute urinary retention, UTIs, bladder neck contracture and urethral stricture were analysed although no significant differences between TURP and PVP interventions were identified. However, PVP had two distinct disadvantages when compared with TURP. PVP appears to be associated with a higher risk of developing dysuria and for reintervention. Dysuria rates after PVP have been reported to be between 6% and 30%.[@R33] There may be several reasons for this, although most likely postoperative dysuria is caused by thermal damage and oedema in urethral tissue. Also, shorter catheterisation times could be another cause of this irritable symptom. That said, research suggests this symptom is generally classified as mild to moderate across all patients, and therefore can be effectively managed, if not resolved altogether within 2 months of follow-up.[@R27] As such, transient dysuria is not a serious PVP complication, the more serious complication is reintervention.

There may be a number of reasons post-PVP patients are at a higher risk of re-intervention. There may be inadequate energy delivery, leading to incomplete tissue removal which might play an important role regarding the outcome of the procedure.[@R38] According to our analysis, those who received an 80W PVP intervention were at significantly higher risk of reintervention compared with TURP. However, researchers have found the differences between other higher power PVP laser groups (ie, 120W, 160W and 180W) and TURP cohort are not statistically significant. Although the GOLIATH study suggests that the 180W XPS laser system is superior to TURP when considering this particular parameter. Logically, this type of adverse event would markedly decrease with the advent of higher power laser systems.

As well as having a higher risk of dysuria and reintervention, PVP is administered in the absence of histological tissue examination, which might limit opportunities to incidentally identify prostate cancer. In order to address this, clinicians might want to consider when there is a rapidly increasing, or higher levels of prostate-specific antigen (PSA), it might be more beneficial to use TURP rather than laser evaporation techniques. In addition, an extensive examination including PSA measures, digital rectal examinations and ultrasonography could be used to guide prostate biopsies administration, if cancer is suspected.[@R12] Prostate cancer is often diagnosed in the late stages which is nearly always too late and therefore *opportunities* to diagnose this insidious disease must not be disregarded.

LUTS manifest secondarily through BPH and is a chronic health condition. The management of these symptoms create additional economic burden for patients and healthcare systems, generally.[@R2] It is vital to evaluate the cost effectiveness of the two surgical therapies in clinical practice. Based on a cost-effectiveness analysis, Armstrong *et al* suggest that the PVP procedure is unlikely to be cost effective because of the relatively expensive consumables.[@R47] However, Patel argues that there is an absence of high-quality and long-term data, in fact only two RCTs with short-term follow-ups were available at the time.[@R48] This meta-analysis suggests that any initial investment in equipment and surgeon's training may be at least partially offset by shorter lengths of hospitalisation and lower incidence of postoperative complications for PVP compared with TURP. Considering high number of cases each year, PVP may actually lower the demand for medical resources in this field, although this also requires further research.

This meta-analysis was undertaken using all currently available comparative clinical studies, however; there are some limitations. First of all, despite designing a systematic search strategy, our inclusion criteria meant that non-English documents were omitted, therefore there must be some language bias. Second, there are very few RCTs with long-term follow-up endpoints in this field of interest which must be addressed. To overcome this, we designed this study to incorporate five prospective cohort studies which added a layer of sophistication to this analysis.

None of the RCTs included described blinding methods which is considered a distinct quality deficit but this is to be expected given the nature of the interventions explored. Actually, this perhaps highlights the need to use the Consolidated Standards of Reporting Trials (CONSORT) quality appraisal method or the Delphi method in further studies. While studies have demonstrate high levels of agreement[@R49] between these quality assessment tools and the methods implemented in this meta-analysis, the CONSORT and Delphi methods contain an increased number of variables and are therefore more likely to differentiate. A more substantial concern, however, is that several studies did not report withdrawal or drop outs. This appears to have been is significant factor in our quality assessment and must be addressed in further research. Third, there was consistently, substantial to extreme heterogeneity across this study sample. Sensitivity analysis only partially accounted for such high levels of heterogeneity. Increased sample sizes, or multicentre trials involving larger numbers of participants as well as reporting age stratification may elaborate on our present understanding. Despite these limitations, this study provides the most up-to-date information concerning the comparison of PVP and TURP in surgical management of BPH.

Conclusion {#s7}
==========

These findings confirm previous studies which suggested that PVP is superior in long-term efficacy to TURP. PVP appears to have only slightly increased IPSS, Qmax, QoL, PVR and IIEF benefit, but is associated with fewer complications. As such, we recommend PVP is offered as the first-line treatment for LUTS secondary to BPH rather than the traditional TURP method. The only addendum is that PVP cannot acquire histological tissue examination which removes an opportunity to identify prostate cancer. Withdrawals and drop outs are not always reported in full and there is a need to use a more comprehensive quality assessment tool to appraise studies in this field. Further research is of course necessary, and should be conducted with larger samples, over longer periods.
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